- 1 Quantification of Fundus
- ² Autofluorescence Features in a
- ³ Molecularly Characterized Cohort of
- 4 More Than 3500 Inherited Retinal
- 5 Disease Patients from the United

6 Kingdom

- 7 William Woof^{1,2*}, Thales A. C. de Guimarães^{1,2*}, Saoud Al-Khuzaei^{3*}, Malena Daich Varela^{1,2*},
- 8 Sagnik Sen^{2,1*}, Pallavi Bagga^{1,2}, Bernardo Mendes^{1,2}, Mital Shah^{1,2}, Paula Burke⁴, David
- 9 Parry⁴, Siying Lin^{1,2}, Gunjan Naik^{1,2}, Biraja Ghoshal^{1,2}, Bart Liefers^{1,9}, Dun Jack Fu^{1,2},
- 10 Michalis Georgiou^{1,2}, Quang Nguyen^{1,2}, Alan Sousa da Silva², Yichen Liu¹, Yu Fujinami-
- 11 Yokokawa⁷, Dayyanah Sumodhee^{1,2}, Praveen Patel^{1,2}, Jennifer Furman¹, Ismail Moghul^{1,2},
- 12 Mariya Moosajee^{1,2}, Juliana Sallum⁸, Samantha R. De Silva³, Birgit Lorenz⁵, Frank Holz⁶,
- 13 Kaoru Fujinami⁷, Andrew R Webster^{1,2}, Omar Mahroo^{1,2}, Susan M. Downes³, Savita
- 14 Madhusudhan⁴, Konstantinos Balaskas^{1,2*}, Michel Michaelides^{1,2*}, Nikolas Pontikos^{1,2*}
- 15
- 16 ¹ University College London Institute of Ophthalmology, 11-43 Bath Street, London, UK
- 17 ² Moorfields Eye Hospital NHS Foundation Trust, 162 City Road, London EC1V 2PD, UK
- 18 ³ Oxford Eye Hospital, John Radcliffe Hospital, Oxford OX3 9DU, UK
- 19 ⁴ St Paul's Eye Unit, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
- 20 ⁵ Transmit Centre of Translational Ophthalmology, Justus-Liebig-University Giessen, Germany
- ⁶ Department of Ophthalmology, University Hospital Bonn, Bonn, Germany.
- ⁷ Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs,
- 23 National Hospital Organization Tokyo Medical Center
- ⁸ Department of Ophthalmology and Visual Sciences, Escola Paulista de Medicina, Federal University
 of Sao Paulo
- ⁹ Department of Ophthalmology and Epidemiology, Erasmus MC, Rotterdam, The Netherlands
- 27
- 28 * Authors contributing equally
- 29
- 30 Corresponding author: <u>n.pontikos@ucl.ac.uk</u>
- 31

32 Abstract

- 33 Purpose: To quantify relevant fundus autofluorescence (FAF) image features cross-
- 34 sectionally and longitudinally in a large cohort of inherited retinal diseases (IRDs) patients.
- 35 **Design:** Retrospective study of imaging data (55-degree blue-FAF on Heidelberg Spectralis)
- 36 from patients.
- 37 Participants: Patients with a clinical and molecularly confirmed diagnosis of IRD who have
- 38 undergone FAF 55-degree imaging at Moorfields Eye Hospital (MEH) and the Royal
- 39 Liverpool Hospital (RLH) between 2004 and 2019.
- 40 **Methods:** Five FAF features of interest were defined: vessels, optic disc, perimacular ring of
- 41 increased signal (ring), relative hypo-autofluorescence (hypo-AF) and hyper-
- 42 autofluorescence (hyper-AF). Features were manually annotated by six graders in a subset
- 43 of patients based on a defined grading protocol to produce segmentation masks to train an
- 44 AI model, AIRDetect, which was then applied to the entire MEH imaging dataset.
- 45 Main Outcome Measures: Quantitative FAF imaging features including area in mm² and
- 46 vessel metrics, were analysed cross-sectionally by gene and age, and longitudinally to
- 47 determine rate of progression. AIRDetect feature segmentation and detection were validated
- 48 with Dice score and precision/recall, respectively.
- 49 **Results:** A total of 45,749 FAF images from 3,606 IRD patients from MEH covering 170
- 50 genes were automatically segmented using AIRDetect. Model-grader Dice scores for disc,
- 51 hypo-AF, hyper-AF, ring and vessels were respectively 0.86, 0.72, 0.69, 0.68 and 0.65. The
- 52 five genes with the largest hypo-AF areas were CHM, ABCC6, ABCA4, RDH12, and RPE65,
- 53 with mean per-patient areas of 41.5, 30.0, 21.9, 21.4, and 15.1 mm². The five genes with the
- 54 largest hyper-AF areas were BEST1, CDH23, RDH12, MYO7A, and NR2E3, with mean
- areas of 0.49, 0.45, 0.44, 0.39, and 0.34 mm² respectively. The five genes with largest ring
- areas were CDH23, NR2E3, CRX, EYS and MYO7A, with mean areas of 3.63, 3.32, 2.84,
- 57 2.39, and 2.16 mm². Vessel density was found to be highest in *EFEMP1*, *BEST1*, *TIMP3*,
- 58 *RS1*, and *PRPH2* (10.6%, 10.3%, 9.8%, 9.7%, 8.9%) and was lower in Retinitis Pigmentosa
- 59 (RP) and Leber Congenital Amaurosis genes. Longitudinal analysis of decreasing ring area
- in four RP genes (*RPGR, USH2A, RHO, EYS*) found *EYS* to be the fastest progressor at
 -0.18 mm²/year.
- 62 **Conclusions:** We have conducted the first large-scale cross-sectional and longitudinal 63 quantitative analysis of FAF features across a diverse range of IRDs using a novel AI 64 approach.
- o- ap
- 65
- 66
- 67

68 Introduction

69 Inherited retinal diseases (IRDs) are clinically and genetically heterogeneous disorders that 70 affect the retina and represent the leading cause of legal blindness among working-age 71 adults in England and Wales, and the second commonest cause in childhood¹. A recent 72 study from Austria, covering nine federal states, has also shown that IRDs are now the 73 leading cause of registered blindness in Austrian children and working-age adults². This group of disorders can be caused by genetic variants in any one of over 300 genes ^{3–5}. 74 75 76 Many IRDs are associated with structural changes within the retina, which can be detected 77 with retinal imaging using different imaging modalities such as colour fundus, infrared-78 reflectance (IR), spectral-domain optical coherence tomography (SD-OCT), or fundus 79 autofluorescence (FAF). FAF is of particular importance in the context of IRDs, as it allows 80 the detection of patterns of fluorophores, often at the level of the photoreceptors and retinal 81 pigment epithelium (RPE), which can be indicative of pathological changes such as loss of 82 overlying photoreceptors ^{6,7}. Some of these FAF signal changes are highly characteristic of 83 specific IRDs and can indicate features such as areas of RPE atrophy or lipofuscin deposits. 84 FAF is listed as a primary or secondary outcome in multiple clinical trials, and it has become 85 a useful retinal biomarker for diagnostic and prognostication purposes in a wide variety of IRDs 4,6,8,9. 86

87

88 The identification and quantification of disease-associated features within retinal imaging is 89 critical for diagnosis, monitoring disease progression, providing prognostic information and 90 assessing treatments in IRDs. The first steps in quantifying retinal imaging-based 91 biomarkers of disease involves identification and segmentation of these features. Manual 92 segmentation performed by human annotators is time-consuming and requires expert 93 annotators, which makes this process subjective and not feasible on a large scale. 94 Automated identification and segmentation of IRD features in a reliable way is important for 95 enabling the routine use of these data quantitatively in clinical practice and to help further 96 our understanding of these diseases.

97

98 Existing studies that have used deep learning to segment IRD features from retinal images
99 have so far focused on specific IRD phenotypes such as retinitis pigmentosa (RP), Stargardt
100 (STGD1), and choroideremia (CHM) ^{10,11}.

101

To support our analysis on a broad range of different IRD phenotypes, we developed
 AIRDetect, a deep learning model that can automatically identify and segment relevant
 features from FAF images. We apply AIRDetect to the entire cohort of IRD patients with

- 105 molecularly confirmed diagnoses at Moorfields Eye Hospital (MEH), to identify genotype-
- 106 phenotype associations, as well as quantify disease progression.

107

108 Methods

109 Dataset Curation

- 110 Patients' genotypes were extracted from the Genetics database of MEH (London, UK) ^{3,12}.
- 111 Patients' images were exported from the Heidelberg Imaging (Heyex) database (Heidelberg
- 112 Engineering, Heidelberg, Germany) based on their hospital number, for records between
- 113 2004-06-17 and 2019-10-22. All 55-degree FAF images were 488nm blue-FAF images
- 114 captured by the Heidelberg Spectralis and the HRA2 imaging platforms.
- 115

116 A dataset of 736 blue-FAF images (55-degree) from 573 patients from MEH were annotated 117 with four different image features, optic disc, regions of hyper- and hypo-autofluorescence 118 (AF), and perimacular ring of increased signal, and a further set of 206 blue-FAF images 119 (55-degree) from 127 patients from the Royal Liverpool Hospital (RLH) were annotated with 120 the retina vessel tree. A grading protocol was defined for IRD retinal feature annotations (Table 1)¹³. The Dice similarity coefficient score was used to assess inter-grader agreement 121 122 ¹⁴. The Dice similarity coefficient is defined as twice the area of overlap between two 123 annotations divided by the total area occupied by the two annotations. It ranges from one for 124 perfect overlap between two annotations to zero for no overlap between two annotations. 125 The intergrader agreement was not found to be significantly different between the graders. 126 Manual grading was completed over an 18-month period from June 2022 to December 2023 127 by four graders, with two additional graders carrying out the vessel segmentation at RLH. 128 The four MEH graders were research fellows with over 5 years' experience in medical retina, 129 three of which had 3 years' experience with FAF scans and IRDs. The two RLH graders 130 were staff from the RLH Reading Centre with over 5 years' experience in vessel annotation 131 on FAF scans. Manual grading was performed using the Moorfields Grading Portal online 132 platform (grading.readingcentre.org). A full breakdown of the manually annotated dataset is 133 given in Supplementary Table 1. 134

Name	Shorthand	Includes	Excludes
Optic Disc	disc	The optic nerve head. Includes both the optic cup and rim.	Peripapillary atrophy not included in annotation.
Hypo- autofluorescence	hypo-AF	Areas distinctly darker than physiological normal area with 50% grader confidence. The level of hypo-AF should be at least 90- 100% as dark as the optic disc. This is defined as Definitely Decreased AF (DDAF) in the literature ^{15,16} Note this is relative AF rather than absolute AF.	Excludes peripapillary atrophy. Areas of ambiguous (not definitely decreased) regions in the periphery are not annotated as hypo-AF.
Hyper- autofluorescence	hyper-AF	Regions brighter than physiological normal area with 50% grader confidence. Note this is relative AF rather than absolute AF.	Excludes macular ring. Excludes flecks.
Perimacular ring of increased signal	ring	Ring shaped area of hyper-AF within the vascular arcades at the macula.	Must be >50% complete circle.
Veins and Arteries	vessels	All visible retinal vessels stemming from the optic disc.	Only annotated over atrophy if the grader is more than 50% certain of the location of the vessel.
136 Table 1: Feature	ures and definit	tions used during the annotation process of five	e features by the graders.

137

138

139 Training and Test Datasets

140 The annotated dataset was compiled, and any images without confirmation for all features 141 from at least one grader at the time of model development were discarded, and, to avoid 142 bias, the annotation from a single grader was randomly selected where multiple grader 143 annotations were available for a single image. After this process there were 554 images from 144 464 patients from MEH. The MEH training set consisted of 506 images from 424 patients. 145 The MEH hold-out test set consisted of 48 images from 40 patients. The RLH training set 146 consisted of 72 images from 52 patients from RLH. The RLH hold-out test set consisted of 23 images from 22 patients. Training sets were split into five separate sets for use with 5-fold 147 148 cross validation, ensuring a balanced representation of each class across folds. Assignment 149 to the training and test sets was done at patient-level to avoid any potential data leakage. 150 The data flowchart is fully described in **Supplementary Figure 1**. 151

152 Development of AIRDetect Segmentation Model

153 For training the AIRDetect segmentation model, we selected the nnU-Net (no-new-UNet)

154 framework for its adaptability and performance in automatic medical image segmentation

155 tasks ¹⁷. At its core, nnU-Net leverages a fully convolutional network design inspired by the

- 156 U-Net architecture, renowned for its efficacy in medical imaging tasks ^{18–20}. The overlying
- 157 nnU-Net framework then automatically configures its network architecture, preprocessing,
- 158 and training strategy based on the dataset's characteristics, optimising for performance,
- without requiring manual hyperparameter tuning or architecture modifications from the user.
- 161 For the five different image features, we trained two separate nnU-net models. A single
- 162 multi-class model for disc, hyper-AF and hypo-AF, and ring, and a separate single-class
- 163 model for vessels. As with common practice for nn-Unet each model consisted of an
- 164 ensemble of five U-nets with identical architectures, but different weights, trained
- 165 independently and then ensembled at inference, taking the unweighted average of the
- 166 probability scores across networks.
- 167
- 168 The model was trained using a sum of Dice and cross-entropy loss functions to optimise for
- 169 multi-class segmentation accuracy. Hyperparameters, such as learning rate and batch size,
- 170 were selected by the nnU-Net based on its analysis of the dataset. Training was curtailed at
- 171 200 epochs as this was sufficient to achieve convergence in most cases.
- 172

173 Validation of AIRDetect Segmentation Model

- 174 Model validation was assessed using the Dice coefficient between the model predictions and
- 175 the corresponding grader annotation on the hold-out test set. Where images were double-
- 176 graded, we took the mean of the model-grader Dice for each grading. We also analysed the
- 177 accuracy of the model-grader agreement for simple presence/absence detection where we
- 178 counted cases as positive for which the model/annotator marked at least some part of the
- 179 image for the given feature, and negative otherwise, from which we derived
- 180 presence/absence detection accuracy, precision and recall.

181 Automatic Annotations on Real World IRD Dataset

- 182 The trained models were applied to automatically segment 45,749 FAF images (55-degree)
- 183 from 3,606 IRD patients with a molecularly confirmed diagnosis from MEH covering 170
- 184 genes ^{3,12}. This took on average 1 second per image parallelised over four 3090 Nvidia
- 185 GPUs amounting to approximately 3-4 hours in total. In comparison a human grader could
- 186 take 5-30 minutes per scans amounting to 5-3 months in total. Images where the optic disc
- 187 was not segmented by the model were removed, as these images were of poor quality or not
- 188 centred on the macula (**Supplementary Figure 2**). Results were analysed from 33,042 FAF
- 189 images from 3,496 patients, after filtering.
- 190

191 For each of the generated masks we extracted: a) if the feature was present or absent; b) 192 the area, number of pixels in the segmented mask multiplied by the resolution; c) the number of connected components, found using watershed clustering ²¹; d) feature brightness, mean 193 194 intensity of pixels from the region covered by the segmented mask. For vessels, we 195 calculated a selection of metrics defined in Supplementary Table 2, using the provided code from the reti-py library as used in the AutoMorph repository ²². Features were also 196 197 analysed based on their distance from the fovea. 198 199 To calculate rate of progression for a given feature, a linear regression was fit to each 200 patient-eye, taking time since the first appointment (in years) as the independent variable, 201 and taking the calculated areas of the segmented feature at each time-point as the 202 measured variable. The slope of the regression was then averaged across eyes per-patient 203 to give a rate of progression. Where multiple scans per eye were present for a given date, 204 we took the most recent scan with the rationale that good quality scans were less likely to 205 lead to further imaging by the operator.

206

207 Results

208 AIRDetect Model Validation

209

210 Examples of AIRDetect segmentation output are presented in **Figure 1**. Model-grader Dice

scores for disc, hypo-AF, hyper-AF, ring and vessels were respectively 0.86, 0.72, 0.69, 0.68

and 0.65, with intergrader Dice scores of 0.82, 0.75, 0.72, 0.80, 0.95, respectively. Model

213 detection accuracy ranged from 77% to 83% (excluding anatomical features) (**Table 2**).

214 Features which were the most challenging to detect were hyper-AF and ring as those had

215 the lowest precision scores at 0.53 and 0.60 respectively.



219 Figure 1: Examples of manually and automatically segmented masks for the five features: vessels, 220 disc, ring, hyper- and hypo-autofluorescence. The vessel dataset was separate to the rest of the data, 221 so vessel visualisation is separate from other features.

- 222
- 223

225 Table 2: Segmentation model training data and results. Dice score quantifies the model's

226 segmentation performance and presence/absence quantifies its feature detection performance. Total

227 = number of annotated images. Incidence = percent of images with gradable feature. Dice inter-grader

= inter-grader agreement of double-graded images (repeated from **Table 2** for reference). Dice model-

229 grader = Dice score between model and graders, with mean scores used when images were double-

230 graded.

	Ті	ain set	Test	t Set	Segme (D	entation ice)	Detection (Presence/Absence)			
Feature	Total	Incidence	Total	Incidence	Inter- grader	Model- grader	Accuracy	Precision	Recall	
disc	506	98%	48	98%	0.82	0.86	-	-	-	
hypo-AF	506	70%	48	44%	0.75	0.72	83.3%	0.81	0.81	
hyper-AF	506	18%	48	23%	0.72	0.69	79.2%	0.53	0.82	
ring	506	32%	48	31%	0.80	0.68	77.1%	0.60	0.80	
vessels	72	100%	23	100%	0.94	0.65	-	-	-	

231

232 Genotype-phenotype Associations

233

234 Analysing associations between identified features and genes across most common genes

235 (Supplementary Table 3), the five genes with the largest hypo-AF areas were CHM,

236 ABCC6, ABCA4, RDH12, and RPE65, with mean per-patient areas of 41.5, 30.0, 21.9, 21.4,

and 15.1 mm² (Figure 2a). The five genes with the largest hyper-AF areas were BEST1,

238 CDH23, RDH12, MYO7A, and NR2E3, with mean areas of 0.49, 0.45, 0.44, 0.39, and 0.34

239 mm² respectively (**Figure 2b**). The five genes with largest ring areas were *CDH23*, *NR2E3*,

240 CRX, EYS and MYO7A, with mean areas of 3.63, 3.32, 2.84, 2.39, and 2.16 mm² (Figure

241 2c). At the gene variant level, ABCA4 p.(Gly1961Glu) showed a higher ring area than other

common ABCA4 variants (Supplementary Figure 4). Vessel density was found to be

243 highest in *EFEMP1*, *BEST1*, *TIMP3*, *RS1*, and *PRPH2* (10.6%, 10.3%, 9.8%, 9.7%, 8.9%)

and was lower in Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis associated

genes (Figure 2d). A full breakdown of features across the 30 most common genes is given

in **Supplementary Table 3**, for all genes in **Supplementary Table 4** and for vessels in

247 Supplementary Table 5.



249 250

Figure 2: Mean a) extent of hypo-AF, b) extent of hyper-AF, c) extent of ring, and, d) Vessel density 251 (ratio between area of vessels and total image area) across the 30 most common genes (RPE65 252 included for reference). Error bars denote standard error. Values were first averaged by patient before 253 averaging by gene to minimise correlations due to multiple contributions from individual patients. 254 Genes are grouped into approximate phenotype groupings denoted by bar styling. 255

256 We analysed how features vary with distance from the fovea by looking at the prevalence of 257 each feature in each 0.5 mm annulus moving away from the fovea. Figure 3 compares 258 prevalence of hyper- and hypo-AF at different distances from the fovea in five different 259 genes (see Supplementary Figure 7 for scale). The two genes associated largely with 260 maculopathy or cone-rod dystrophy (ABCA4, PRPH2) show increased area and prevalence 261 of hypo-AF at the fovea (Figure 3.a and Figure 2.a) but reducing proportions of the retina 262 displaying hypo-AF moving away from the fovea. The two RP-associated genes (USH2A, 263 RPGR) show less hypo-AF across the whole retina compared with the cone-rod genes, but 264 with a bimodal profile, with the greatest relative proportion of hypo-AF at the fovea followed 265 by 4-6mm from the fovea, just within the vascular arcade. For CHM, unlike the other genes, 266 there was the least hypo-AF at the fovea, but substantially increased hypo-AF away from the 267 fovea. For hyper-AF there is an increased proportion of hyper-AF at the fovea in all genes 268 except ABCA4 that reduces further from the fovea (Figure 3b). In the two RP-associated 269 genes (USH2A, RPGR) there is an increase in hyper-AF at 1-3mm from the fovea.



Figure 3: Autofluorescence (AF) as a proportion of total altered AF area in the image compared with distance from fovea for patients with variants in *ABCA4*, *RPGR*, *USH2A*, *RPGR*, and *CHM* for a) hypo-AF and b) hyper-AF.

275

271

In Figure 4 the area of hyper-AF within 1.5mm of the fovea is compared against patient age
for five different IRD genes. Most genes showed an increase with age, with the exception of *PRPH2*, which remained fairly stationary, and *BEST1*, which demonstrated a sharp
decrease with patient age - although there was a considerable variability across ages within
all genes.

281



Figure 4: hyper-AF area within 1.5mm of the fovea (corresponding to inner 3mm ETDRs ring) compared with patient age. Least-squares regression line in red. Significant increase in hyper-AF with age for *ABCA4* (β =691 µm²/yr, p<0.001), *USH2A* (β =4090µm²/yr, p<0.001) and *RPGR* (β =2520µm²/yr, p<0.029). Significant decrease for *BEST1* (β =-6500µm²/yr, p<0.001). No significant changes of hyper-AF with age were found for *PRPH2*.

- 288
- 289
- 290
- 291

292

293 Disease Progression

We applied AIRDetect longitudinally to monitor progression within individual patients across multiple visits. **Figure 5** shows an example using AIRDetect to visualise the decrease in ring area in individual patients with RP associated with variants in four different genes, namely *USH2A, PRPH2, RHO* and *EYS*. Comparing these four RP genes in the entire MEH IRD cohort, average rate of decrease in total ring area was greater in patients with RP associated with *EYS* (-0.178 mm²/year), *USH2A* (-0.066 mm²/year), and *RPGR* (-0.046 mm²/year), when compared to *RHO* (-0.040 mm²/year).

301

302 We also applied AIRDetect to monitor progression in patients belonging to three subgroups 303 of ABCA4 (Figure 6). Patients were classified into three groups (A, B and C) based on increasing severity of genetic variants as defined by Cornelis et al. ^{23,24}. Patients in group A 304 305 had two severe variants, while group C had a mild variant in trans with any other variant. 306 Patients with variants of known severity whose combination do not fit the other two groups 307 were placed into group B. The average increase in hypo-AF area per year was compared between groups (**Supplementary Figure 3**). In keeping with previous studies ^{25–29}, the mean 308 309 per-patient rate of increase in hypo-AF area was highest in the highest severity classification 310 (group A), at 3.11 mm²/year (0.294 mm/year change in square root area), followed by 1.59 311 mm^2 /year (0.169 mm/year) for the intermediate severity group (B), and finally 0.87 mm²/year 312 (0.108 mm/year) in the lowest severity group (C) (Supplementary Table 6). 313



- 315 Figure 5: Automatic monitoring of lesion size for disease progression. Decreasing area of ring for four
- 316 patients with disease-causing variants in: a) RPGR, b) USH2A, c) RHO, and d) EYS. In these genes,
- the macular ring is expected to shrink in diameter over time as the disease progresses.

318



319 320

Figure 6: Increasing area of hypo-AF for two patients of each of the three ABCA4 severity groups: a)

321 group A, b) group B and c) group C. Here we see the expected patterns of progression reported in

322 Supplementary Table 6 with A being the fast progressors, followed by B and C.

323 Discussion

324 The results of our cross-sectional analysis match known genotype-phenotype associations 325 demonstrating the validity of our approach, as well yielding novel insights. For example in 326 Figure 2.a, CHM and ABCA4 both exhibited higher levels of hypo-AF, consistent with the 327 large areas of atrophy that spare the fovea in choroideremia, as well as the macular atrophy typically seen in STGD1 disease (ABCA4)^{8,30-32}. Of interest however, ABCC6 which is 328 329 associated with pseudoxanthoma elasticum was identified to have second largest areas of 330 hypo-AF. On further inspection, these could be explained by the large angioid streaks 331 characteristic of this condition which can appear as hypo-AF on FAF³³. For hyper-AF, BEST1 332 exhibited the largest areas of hyper-AF, which can be attributed to the vitelliform lesion(s) 333 that are characteristically observed in autosomal dominant and recessive forms of the 334 disease ^{34–36} (Figure 2.b). For ring the presence of a macular ring typically corresponds to a 335 demarcation between diseased and non-diseased retina, and is usually seen in RP and cone 336 rod dystrophies, in keeping with our findings herein ⁴ (Figure 2.c). The lower vessel density 337 observed in RP and LCA genes was also in keeping with the vessel attenuation commonly associated with these genes^{37,38} (Figure 2.d). As well as genotype-phenotype associations, 338 339 we also found associations at the individual variant level confirming known association 340 between the p.(Gly1961Glu) variant in ABCA4 and presence of a macular ring ^{39–42} 341 (Supplementary Figure 3). When considering feature prevalence from the fovea, we found, 342 as expected, that genes usually associated with cone-rod degeneration showed a decrease 343 in hypo-AF extent moving away from the fovea, but with an opposite trend for the RP genes 344 and CHM (Figure 3). Hyper-AF was mainly concentrated at the fovea, but with a distinctive 345 peak at 2-3mm from the fovea which may be attributed to partial macular rings classified as 346 hyper-AF by our model (Figure 3.b). PRPH2 also had a higher coverage of hyper-AF in the 347 fovea when compared to ABCA4 which is consistent with the pattern/macular dystrophy and adult vitelliform phenotypes associated with PRPH2⁴³ (Figure 3.b). 348 349

In our longitudinal analysis we were able to replicate the findings of Fakin et al. 2016 in 350 351 Figure 7 and Table 4, where we found that growth of areas of hypo-AF was much more 352 rapid in the group associated with more severe ABCA4 genetic variants ²⁵. Our estimates for 353 rate of progression were higher than that previously reported, which may be due to the use 354 of 55-degree as opposed to 30-degree imaging in our dataset and hence a larger area of hypo-AF^{28,44}. Comparing hyper-AF across patient age in Figure 4, the hyper-AF within 355 356 1.5mm of the fovea increased for ABCA4, USH2A and RPGR, consistent with lesions 357 developing with disease progression over time. However, there were some noteworthy 358 exceptions for individual genes. In particular, BEST1 is associated with "yolk-like" regions of 359 hyper-AF, typically within 2-3 mm of the perifovea, which change over time through pre-

vitelliform, vitelliform, pseudohypopyon, vitelliruptive stages and finally to the atrophic stage
 ^{4,36}. The highest hyper-AF signal would be associated with the vitelliform stage, progressively
 reducing in intensity to become a region of hypo-AF by the atrophic stage, which matches
 what we see as a decrease in foveal hyper-AF with age. No significant progression of
 hyper-AF with age was detected for *PRPH2* which is likely due to the later onset of the
 condition in most patients (typically after 45 years of age) and hence a more limited age
 range, as well as the milder pattern of dystrophy ⁴⁵

We also identified increased rate of decrease in area of macular ring in *EYS*, *USH2A* and *RPGR* compared to *RHO* (**Figure 6**). Monitoring the rate in which the macular ring narrows down is common practice in generalised retinal dystrophies such as RP⁶. A more rapid encroachment of the macular ring in autosomal recessive (*USH2A*, *EYS*) and X-linked (*RPGR*) genes compared to the autosomal dominant *RHO*, is consistent with the latter having a slower disease progression compared to the others⁴⁶.

374

375 To date, deep learning AI models to analyse FAF images from IRD patients have been 376 limited. There have been studies developing classification models of FAF images based on IRD phenotypes ^{47–50}. But as to segmentation approaches, areas of hypo-AF have been 377 378 measured either manually or semi-automatically using RegionFinder on HEYEX2 software to study the progression rate of the area of atrophy in STGD1 disease ^{51–54}. These 379 380 approaches compared to deep-learning approaches would be challenging to scale 381 accurately to our real-world dataset as they require considerable parameter tuning compared 382 to deep-learning based approaches such as AIRDetect. Previous deep-learning based 383 segmentation approaches have mostly focused on STGD1 to segment for hypo-AF⁵⁵ or 384 flecks¹¹. Hence our AIRDetect approach represents the first to be developed and applied to 385 a wide range of IRDs covering 170 genes.

386

387 One limitation of our approach is that the gene associations described in our study are 388 limited by the variation in phenotypes which can occur with stage of disease for progressive 389 conditions, different variants in the same gene or different modes of inheritance. Examining 390 distribution of best corrected visual acuity per gene in our data, we can confirm that a range 391 of disease stages are present in our dataset (Supplementary Figure 8). In terms of 392 examples of phenotype variability per gene, CRX can be associated with a mild CORD but also quite severe LCA ⁵⁶⁻⁵⁸. RPGR can be associated with RP, LCA, macular dystrophy and 393 394 CORD ^{59,60}. We conducted a sub analysis in ABCA4 (Supplementary Figure 4) but have 395 not yet conducted this analysis across all gene variants and modes of inheritance.

397 Other limitations are the limited sample size for some of the genes and the large variance in 398 imaging quality in our real-world dataset in part due to the discomfort of the patient to 399 potential blue light-toxicity⁶¹, which affects the reliability of some of the features in lower 400 quality images. While automatic image quality assessment tools exist for colour fundus retinal imaging ⁶², none have been developed for FAF imaging. Assessing image quality can 401 402 also be particularly challenging for IRDs as they are associated with a wide range of 403 pathologies, many of which can affect perceived image quality, as well as make it more 404 challenging for the operator to acquire good quality images. We plan to develop an IRD FAF 405 image quality assessment model in future, which should help to improve the consistency of 406 our segmented masks and reduce noise in our analysis. 407 408 We anticipate that AIRDetect can be used to validate further clinically relevant findings, as 409 well as identifying new potential associations between different feature patterns and certain 410 genes or variants. Our approach could also be applied to identifying structure-function 411 association (Supplementary Figure 5) as well as cross-modality image registration tasks by 412 using vessel-based segmentation to align images (Supplementary Figure 6). Besides 413 IRDs, the diverse nature of IRD-associated pathologies might make AIRDetect useful to 414 improve robustness for segmentation of FAF imaging for other non-IRD conditions or provide 415 a good starting point for developing models for specific conditions where data is more scarce 416 or to other imaging modalities such as ultra-widefield imaging, via transfer learning. 417 418 In conclusion, we have conducted, to our knowledge, the largest quantitative cross-sectional 419 and longitudinal analysis of FAF features across a diverse range of IRDs in a real world

420 dataset, enabled by our novel automatic segmentation AI model, AIRDetect.

421 Ethics

- 422 This research was approved by the IRB and the UK Health Research Authority Research
- 423 Ethics Committee (REC) reference (22/WA/0049) "Eye2Gene: accelerating the diagnosis of
- 424 inherited retinal diseases" Integrated Research Application System (IRAS) (project ID:
- 425 242050). All research adhered to the tenets of the Declaration of Helsinki.

426

427 Code availability

- 428 The source code for the AIRDetect model architecture training and inference is available
- 429 from https://github.com/Eye2Gene/. The model weights of AIRDetect are intellectual
- 430 proprietary of UCLB so cannot be shared publicly. However, they may be shared via a
- 431 licensing agreement with UCLB. A running version of the AIRDetect app is accessible via the

- 432 Eye2Gene website (<u>www.eye2gene.com</u>) and via the Moorfields Grading Portal
- 433 (grading.readingcentre.org) on invitation.

434

435 Data availability

The data that support the findings of this study are divided into two groups, published data and restricted data. Published data are available from the Github repository. Restricted data are curated for AIRDetect users under a license and cannot be published, to protect patient privacy and intellectual property. Synthetic data derived from the test data has been made available at https://github.com/Eye2Gene/.

441

442 Author contributions

443 WAW analysed the data and wrote the manuscript. NP designed the obtained the funding,

designed the experiments, analysed data and wrote the manuscript. MM, KB, WAW, TACG,

445 SAK, MDV, BM designed the experiments, analysed data and wrote the manuscript. SS

analysed the data. MS wrote the manuscript. PBa analysed the data. PBu, DP analysed the

447 data. All authors have critically reviewed the manuscript.

448 Acknowledgement

449 This work is primarily funded by a NIHR AI Award (AI_AWARD02488) which supported NP, 450 WAW, MM, KB, SD and SM. The research was also supported by a grant from the National 451 Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at Moorfields Eye 452 Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. NP was also previously 453 funded by Moorfields Eye Charity Career Development Award (R190031A). BJ was partially 454 funded by IIR-DE-002818 from Shire/Takeda and by the European Reference Network for 455 Rare Malformation Syndromes, Intellectual and Other Neurodevelopmental Disorders (ERN-456 ITHACA). OAM is supported by the Wellcome Trust (206619/Z/17/Z). AYL is supported by 457 an unrestricted and career development award from RPB, Latham Vision Science Awards, NIH OT2OD032644, NEI/NIH K23EY029246, and NIA/NIH U19AG066567. SA is supported 458 459 by a scholarship from Qatar National Research Fund (GSRA6-1-0329-19010). This project 460 was also supported by a generous donation by Stephen and Elizabeth Archer in memory of 461 Marion Woods. The hardware used for analysis was supported by the BRC Challenge Fund 462 (BRC3_027). We also gratefully acknowledge the support of NVIDIA Corporation with the 463 donation of the Titan Xp GPU used for this research. The views expressed are those of the 464 authors and not the funding organisations.

466 Supplementary

467 Supplementary Figure 1: Data flowchart with number of images, patients, eyes, and genes at each468 stage of AIRDetect model development.



- Supplementary Figure 2: Examples of images with no Disc segmentation from the model. These are
 - either poor quality, have significant atrophy, or are improperly centred.



477 **Supplementary Table 1:** Overview of annotated dataset for the manually segmented features,

478 considering each feature individually. Not all features were gradable within all images, with some

479 images only annotated for some features. Images for vessel annotations were selected by clinicians

480 and were all gradable. Incidence includes ungradable

Feature	Graded	Double graded	Partially Gradable	Un- Gradable	Num Patients	Num Genes	Present	Incidence
disc	736	207	74	32	573	63	716	97.3%
hypo-AF	736	204	75	32	573	63	482	65.5%
hyper-AF	730	191	77	32	570	63	106	14.5%
ring	729	195	76	32	571	63	212	29.1%
vessels	206	13	n/a	n/a	127	33	206	100%

481

482 483

Supplementary Table 2: Vessel metrics and their description.

Vessel Metric	Description
Fractal Dimension	Method that represents geometric complexity of the vascular branching pattern observed in the retina. Essentially how close are the vessels to being "space-filling".
Vessel Density	Ratio between area of vessels and total image area.
Average Width	Average width of vessels.
Distance Tortuosity	Distance tortuosity is a measure of the tortuosity of a path based on the ratio of the actual path length to the straight-line distance between the start and end points of the path 63
Squared Curvature Tortuosity	Squared curvature tortuosity is a more sophisticated measure of tortuosity that takes into account the curvature along the path, providing a detailed view of its winding nature ⁶³
Tortuosity Density	Assesses vessel tortuosity by aggregating local contributions, examining the degree to which each turn curve deviates from a smooth curve ⁶⁴

484 485

.

	Supplementary Table 3: Feature statistics by gene for selected 30 genes. Results are mean across all images. %=Incidence, A=Average Area (mm ²),																				
	D=ves	sel den	sity, F=f	ractal di	mension.	The tab	le cells l	have be	en shad	ed with lo	wer valu	es in red	d, interm	nediate v	alues in v	white and	d larger	values i	n green.	,	(whi
		disc	•	ĺ		I	nypo-AF				h	yper-AF					ring			vessels	, ch v
Gene	Α	с	I	<3mm	%	Α	С	I	<3mm	%	A	С	1	<3mm	%	Α	С	1	<3mm	D	Fs
ABCA4	2.19	1.01	9.20%	13.70%	80.30%	19.81	1.45	11.10%	61.30%	18.00%	0.05	0.33	66.40%	48.30%	33.50%	0.57	1.58	59.60%	81.80%	7.65%	
ABCC6	1.53	1.03	16.90%	17.60%	69.00%	21.44	2.08	14.30%	32.60%	54.90%	0.23	1.2	62.50%	23.40%	8.20%	0.03	0.15	43.30%	38.00%	8.07%	1.37
BBS1	2.59	1.02	10.40%	7.50%	67.50%	8.35	1.29	11.90%	56.90%	25.90%	0.15	0.38	47.30%	86.90%	32.50%	0.84	1.03	56.50%	72.70%	4.56%	1.18
BEST1	1.84	1.01	11.60%	4.10%	40.50%	2.58	0.9	11.50%	59.70%	57.50%	0.73	1.09	61.20%	59.80%	57.50%	1.28	1.83	56.30%	77.20%	9.62%	1.38
CACNA1F	2.04	1.01	14.80%	0.00%	5.70%	0.91	0.2	7.10%	42.40%	12.80%	0.01	0.15	59.80%	2.50%	3.80%	0.01	0.06	53.60%	79.80%	5.35%	1.21 2 0.
CDH23	2.05	1.01	14.30%	6.40%	16.20%	0.71	0.47	10.40%	42.00%	19.60%	0.23	0.5	57.60%	34.20%	77.30%	2.46	2.73	47.30%	67.30%	2.46%	1.05 to 2
CERKL	2.63	1	12.30%	9.10%	82.30%	10.33	1.43	12.10%	51.70%	17.70%	0.02	0.21	46.00%	88.60%	29.70%	1.04	0.95	58.10%	65.30%	3.51%	<u>1.16</u> 页 <mark></mark>
СНМ	1.45	1.06	20.60%	2.80%	82.60%	51.77	3.28	19.90%	21.00%	48.80%	0.26	0.83	54.50%	37.90%	5.50%	0.03	0.08	43.20%	32.20%	6.20%	1.30
CNGA3	1.74	1.01	13.80%	14.50%	31.10%	1.48	0.96	7.10%	56.30%	8.00%	0.05	0.17	54.00%	31.80%	35.60%	0.32	0.75	50.00%	74.90%	5.36%	1.24 J
CNGB3	1.91	0.99	14.90%	12.70%	12.50%	0.16	0.38	6.70%	73.60%	10.40%	0.01	0.12	52.70%	63.90%	32.60%	0.2	0.63	54.60%	92.20%	5.92%	
CRB1	1.97	1.02	14.70%	3.60%	55.20%	8.3	1.22	15.60%	40.40%	44.00%	0.41	0.89	46.40%	54.00%	43.70%	1.73	1.35	48.90%	59.20%	4.27%	1.11 2
CRX	2.11	1	15.60%	5.70%	70.30%	5.51	1.39	15.60%	62.70%	16.90%	0.05	0.26	50.70%	29.90%	59.30%	2.23	4.22	52.90%	65.90%	7.30%	1.83 tho
EFEMP1	1.77	1	15.30%	6.00%	78.70%	5.15	1.84	14.20%	82.40%	77.90%	0.24	1.55	61.80%	79.40%	24.10%	0.18	0.66	60.00%	82.50%	10.10%	1.83 cr/124
EYS	2.36	1.02	15.20%	2.90%	65.90%	9.55	1.64	13.30%	27.30%	23.40%	0.23	0.4	57.60%	42.90%	72.50%	2.08	2.76	52.60%	76.80%	3.07%	
GUCY2D	2	1	14.70%	6.50%	48.00%	5.25	0.86	17.50%	71.20%	17.60%	0.22	0.3	61.20%	36.00%	60.90%	1.51	2.94	53.10%	75.00%	6.91%	1.29,7 80
MYO7A	2.07	0.99	15.80%	2.30%	42.30%	2.37	0.95	18.00%	32.90%	28.00%	0.41	0.97	53.70%	21.80%	73.60%	3.24	3.26	47.00%	57.80%	2.70%	
NR2E3	1.94	1.02	10.90%	7.40%	31.50%	1.42	0.76	10.20%	12.90%	21.40%	0.37	0.5	56.50%	17.90%	39.60%	1.72	1.4	52.20%	24.70%	8.33%	1.al
PDE6B	2.62	1.01	14.80%	3.40%	52.20%	4.48	0.93	17.00%	49.30%	21.30%	0.08	0.28	55.10%	56.90%	86.00%	3.37	4.06	47.30%	86.60%	3.00%	
PROM1	2.3	1.01	12.60%	7.00%	80.00%	12.15	1.72	12.60%	72.00%	21.10%	0.04	0.25	52.30%	72.90%	34.80%	0.85	2.06	54.00%	82.50%	6.10%	1.96 n
PRPF31	2.2	1.03	15.50%	1.20%	48.10%	6.78	1.56	12.00%	41.30%	18.80%	0.12	0.34	45.90%	68.30%	64.00%	2.17	2.85	52.50%	86.90%	4.10%	1.21 äp
PRPH2	2.05	1.01	12.30%	4.50%	68.70%	10.28	1.89	10.10%	62.00%	36.40%	0.07	0.58	59.10%	77.10%	26.30%	0.69	0.85	55.80%	69.40%	8.00%	1.966 ed
RDH12	1.92	1.01	18.00%	11.80%	58.10%	22.35	1.1	19.00%	37.30%	33.70%	0.37	0.52	49.00%	22.10%	34.10%	1.51	2.52	57.90%	84.80%	2.93%	
RHO	2.17	1.03	15.50%	1.50%	61.90%	9.74	1.72	13.60%	34.80%	18.50%	0.11	0.24	53.00%	56.00%	70.60%	2.25	2.99	53.60%	82.80%	4.47%	1.82 a gus
RP1	2.19	1.01	13.70%	5.50%	63.00%	9.32	1.76	13.10%	40.10%	19.10%	0.18	0.27	55.90%	66.70%	65.00%	2.03	2.98	54.60%	74.80%	4.59%	1.233 lice
RP2	2.48	1.05	9.90%	13.30%	47.60%	3.1	1.19	10.50%	48.30%	6.90%	0.02	0.08	54.70%	84.40%	13.00%	0.26	0.38	59.00%	67.80%	3.65%	1.#9nse
RPE65	1.15	1.06	19.30%	7.60%	52.40%	40.13	2.65	15.00%	29.10%	37.80%	0.24	0.65	56.40%	61.80%	4.90%	0.19	0.05	43.10%	97.60%	2.04%	0.97 t 224
RPGR	2.31	1.01	13.70%	3.70%	54.20%	7.78	1.27	14.40%	36.50%	22.60%	0.13	0.31	54.40%	58.60%	61.30%	2.13	2.09	55.90%	82.00%	4.06%	1.190
RS1	1.93	1	11.90%	3.50%	26.80%	2.41	0.58	10.70%	36.70%	24.80%	0.1	0.37	44.30%	73.20%	16.90%	0.35	0.59	53.00%	66.40%	8.69%	1.34 a c
TIMP3	1.71	1.01	17.50%	9.50%	62.10%	16.35	1.84	15.30%	46.50%	30.70%	0.14	0.51	58.50%	32.60%	27.00%	0.47	1	55.20%	35.30%	9.15%	1.39 + 0
USH2A	2.17	1.02	15.60%	2.30%	61.30%	8.47	1.76	13.00%	36.50%	19.80%	0.15	0.31	53.50%	66.50%	72.10%	1.98	3.2	53.50%	87.50%	3.42%	1.1/ pro
All	2.09	1.02	13.50%	6.90%	61.20%	13.04	1.46	13.00%	48.20%	25.10%	0.15	0.43	57.10%	52.80%	43.70%	1.19	1.78	54.10%	77.90%	5.75%	1.250 H
																					nt in perpetu
																					uity.
																				22	eprint

Supplementary Table 4: Feature statistics for all genes. Phenotypes: pheno = most common phenotype presentation according to literature. ACHM = achromatopsia, ALB = albinism, BEST = best disease, CD = cone-dystrophy, CHM = choroidemia, CR = cone-rod, CSNB = congenital stationary night blindness, DR = diabetic retinopathy, FEVR = Familial exudative vitreoretinopathy, GA = Gyrate atrophy, LCA = Leber's congenital amaurosis, MAC = Microphthalmia, anophthalmia, coloboma, MD = macular dystrophy, OA = optic atrophy, PD = pattern dystrophy, PXE = pseudoxanthoma elasticum, RP = retinitis pigmentosa. pat = number of patients. img = number of FAF images. Feature metrics are averaged across all images per gene. Features: % = average incidence in percent, A = average area in mm², C = average number of clusters, I = average pixel intensity in percentage, % <6mm = average incidence within 6mm area in percent, FD = vessel fractal dimensions, D = average vessel density, W = average vessel width, DTM = distance tortuosity mean, SCTM = squared curvature tortuosity mean, TDM = tortuosity density mean.

(see online supplementary table 4)

Supplementary Table 5: All vessel metrics across selected genes. Definitions of metrics are given in Supplementary Table 2. The table cells have been shaded with lower values in red, intermediate values in white and larger values in green.

gene	Fractal Dimension	Vessel Density	Average Width	Distance Tortuosity Mean	Squared Curvature Tortuosity Mean	Tortuosity Density Mean
ABCA4	1.33	7.65%	184.81	4.81	61.6	0.71
ABCC6	1.37	8.07%	196.68	6.17	80.7	0.73
BBS1	1.18	4.56%	186.86	9.66	214.9	0.7
BEST1	1.38	9.62%	203.18	4.46	49.4	0.71
CACNA1F	1.21	5.35%	218.03	9.24	83.8	0.73
CDH23	1.05	2.46%	198.91	7.97	177.8	0.68
CERKL	1.16	3.51%	179.55	7.2	95.8	0.67
СНМ	1.3	6.20%	190.34	6.14	104.4	0.69
CNGA3	1.24	5.36%	209.19	5.17	70.9	0.7
CNGB3	1.24	5.92%	205.53	6.42	67.1	0.7
CRB1	1.11	4.27%	178.82	7.2	83.2	0.69
CRX	1.33	7.30%	192.4	9.58	119.5	0.72
EFEMP1	1.43	10.06%	208.55	4.31	39.4	0.72
EYS	1.16	3.07%	172.31	7.39	108.3	0.69
GUCY2D	1.29	6.91%	197.87	5.41	64.4	0.72
ΜΥΟ7Α	1.09	2.70%	182.09	11	296.8	0.7
NR2E3	1.32	8.33%	202.83	5.85	77.5	0.72
PDE6B	1.12	3.00%	181.7	7.22	113.4	0.71
PROM1	1.26	6.10%	179.6	6.5	116.9	0.72
PRPF31	1.21	4.10%	178.26	7.11	146.2	0.7
PRPH2	1.36	8.00%	184.62	4.76	52.1	0.71
RDH12	0.99	2.93%	179.48	3.48	20.6	0.72
RHO	1.22	4.47%	175.72	6.49	86.1	0.69
RP1	1.23	4.59%	174.37	6.93	139.4	0.7
RP2	1.19	3.65%	181.19	6.83	109.3	0.69
RPE65	0.97	2.04%	164.35	6.64	110.8	0.65
RPGR	1.19	4.06%	182.93	8.03	126.1	0.7
RS1	1.34	8.69%	207.5	5.45	62.3	0.72
TIMP3	1.39	9.15%	198.27	4.99	71.9	0.71
USH2A	1.17	3.42%	170.22	7.26	101.6	0.69
All	1.25	5.75%	186.52	6.45	98	0.7

Supplementary Table 6: Average increase in hypo-AF area stratified by ABCA4 variant severity. ABCA4 patients are grouped based on the severity of their genetic variants as proposed by Cornelis et al. 2022 into groups A, B and C²³.

ABCA4 severity classification	Number of Patients	Variant combination	Average increase in hypo-AF area per year (mm²)	Average increase in sqrt hypo-AF area per year (mm)
А	69	Severe/Severe	3.11	0.29
В	75	Intermediate/Intermedia te or Severe/Intermediate	1.59	0.17
С	184	Mild/*	0.87	0.11



Supplementary Figure 3: Rate of progression of hypo-AF in mm² per year for patients in the three severity classification groups of *ABCA4*. Note that Group A has a higher mean rate of progression than groups B and C, as it corresponds to the group with the highest severity. Error bars denote standard error.



Supplementary Figure 4: Comparison of the mean per-patient extent of macular ring present for patients with different variants (i.e. patients with at least one copy of the given variant) in *ABCA4*. Axes are truncated to exclude 99th percentile outliers. Most variants of *ABCA4* are not associated with a macular ring of raised AF, apart from p.(Gly1961Glu) which we see reflected in the different distributions of ring area in our data.



Supplementary Figure 5: hypo-AF area within 1.5mm of the fovea compared to LogMAR best corrected visual acuity (BCVA) where higher values corresponds to poorer acuity. Axes rescaled to 90th pct of data for legibility. Each circle represents a single patient with mean value across images. Least-squares regression line in red (β =0.083, p<0.001). Mean values for select genes are indicated by red crosses. Comparing hypo-AF

area within 1.5mm of the fovea and LogMAR best corrected visual acuity (BCVA) showed a positive statistical association (β =0.083, p<0.001). However, some genes demonstrated a different relationship from the main trend. For example, in *ABCA4* a worse BCVA was observed than might be expected from hypo-AF coverage, likely because *ABCA4*-associated retinopathy usually initially affects the fovea/central macula. By contrast, *CHM* typically exhibits a spared foveal island despite having significant areas of atrophy, thus accounting for the relatively preserved BCVA.



Supplementary Figure 6: Example showing how vessel tree segmentation improves cross-modality image registration. First row shows the individual and overlaid images, and second rows shows corresponding segmented vessel masks. For the overlaid images, the IR image is rendered in red, while the FAF image is rendered in green, enabling overlap to be assessed by looking at the correspondence between the two-colour channels. Vessel trees were extracted using AIRDetect for both the IR and the FAF image. Results of automatic registration directly on the raw images (scans column) and registration on the vessel trees (vessels column) are shown. In both cases this registration was performed using the SimpleElastix package. As shown by the final column, registering using vessel trees results in better overlap than registering using images alone.



Supplementary Figure 7: 55-degree FAF image with 0.5mm, 1.5mm, and 3mm radial distances shown (corresponding to 1mm, 3mm, and 6mm diameter ETDRS regions), and scale bar with 1mm gradations.



Supplementary Figure 8: Distributions of best corrected visual acuity (in LogMar) with respect to 36 genes sorted by the median of the visual acuity distribution per gene. Low vision is defined as a best-corrected visual acuity worse than 0.5 LogMAR but equal or better than 1.3 LogMAR in the better eye. Blindness is defined as a best-corrected visual acuity worse than 1.3 LogMAR. Also represented are Logmar of 1.98 (Counting Fingers), 2.28 (Hand Movement) and 2.7 (Light Perception).

References

1. Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999–2000 with 2009–2010. BMJ Open 2014;4:e004015. Available at: http://bmjopen.bmj.com/content/4/2/e004015 [Accessed December 4, 2017].

2. Glatz M, Riedl R, Glatz W, et al. Blindness and visual impairment in Central Europe. PLoS One 2022;17:e0261897. Available at: http://dx.doi.org/10.1371/journal.pone.0261897.

3. Pontikos N, Arno G, Jurkute N, et al. Genetic Basis of Inherited Retinal Disease in a Molecularly Characterized Cohort of More Than 3000 Families from the United Kingdom. Ophthalmology 2020;127:1384–1394. Available at: http://dx.doi.org/10.1016/j.ophtha.2020.04.008.

4. Georgiou M, Robson AG, Fujinami K, et al. Phenotyping and genotyping inherited retinal diseases: Molecular genetics, clinical and imaging features, and therapeutics of macular dystrophies, cone and cone-rod dystrophies, rod-cone dystrophies, Leber congenital amaurosis, and cone dysfunction syndromes. Prog Retin Eye Res 2024;100:101244. Available at: http://dx.doi.org/10.1016/j.preteyeres.2024.101244.

5. Lee KE, Pulido JS, da Palma MM, et al. A Comprehensive Report of Intrinsically Disordered Regions in Inherited Retinal Diseases. Genes 2023;14. Available at: http://dx.doi.org/10.3390/genes14081601.

6. Daich Varela M, Esener B, Hashem SA, et al. Structural evaluation in inherited retinal diseases. Br J Ophthalmol 2021;105:1623–1631. Available at: http://dx.doi.org/10.1136/bjophthalmol-2021-319228.

7. Delori FC, Dorey CK, Staurenghi G, et al. In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 1995;36:718–729. Available at: https://www.ncbi.nlm.nih.gov/pubmed/7890502.

8. Strauss RW, Kong X, Ho A, et al. Progression of Stargardt Disease as Determined by Fundus Autofluorescence Over a 12-Month Period: ProgStar Report No. 11. JAMA Ophthalmol 2019;137:1134–1145. Available at: http://dx.doi.org/10.1001/jamaophthalmol.2019.2885.

9. Daich Varela M, Laich Y, Hashem SA, et al. Prognostication in Stargardt Disease Using Fundus Autofluorescence: Improving Patient Care. Ophthalmology 2023;130:1182–1190. Available at: http://dx.doi.org/10.1016/j.ophtha.2023.06.010.

10. Wang Y-Z, Juroch K, Chen Y, et al. Deep Learning-Facilitated Study of the Rate of Change in Photoreceptor Outer Segment Metrics in RPGR-Related X-Linked Retinitis Pigmentosa. Invest Ophthalmol Vis Sci 2023;64:31. Available at: http://dx.doi.org/10.1167/iovs.64.14.31.

11. Charng J, Xiao D, Mehdizadeh M, et al. Deep learning segmentation of hyperautofluorescent fleck lesions in Stargardt disease. Sci Rep 2020;10:16491. Available at: http://dx.doi.org/10.1038/s41598-020-73339-y.

12. Lin S, Vermeirsch S, Pontikos N, et al. Spectrum of genetic variants in the commonest genes causing inherited retinal disease in a large molecularly characterised UK cohort. Ophthalmology Retina 2024. Available at: https://www.sciencedirect.com/science/article/pii/S2468653024000137.

13. Nguyen Q, Woof W, Kabiri N, et al. Can artificial intelligence accelerate the diagnosis of inherited retinal diseases? Protocol for a data-only retrospective cohort study (Eye2Gene). BMJ Open 2023;13:e071043. Available at: http://dx.doi.org/10.1136/bmjopen-2022-071043.

14. Dice LR. Measures of the Amount of Ecologic Association Between Species. Ecology 1945;26:297–302.

Available at: http://www.jstor.org/stable/1932409.

15. Kuehlewein L, Hariri AH, Ho A, et al. Comparison of manual and semiautomated fundus autofluorescence analysis of macular atrophy in Stargardt disease phenotype. Retina 2016;36:1216–1221. Available at: http://dx.doi.org/10.1097/IAE.00000000000870.

16. Strauss RW, Muñoz B, Jha A, et al. Comparison of short-wavelength reduced-illuminance and conventional autofluorescence imaging in Stargardt macular dystrophy. Am J Ophthalmol 2016;168:269–278. Available at: http://dx.doi.org/10.1016/j.ajo.2016.06.003.

17. Isensee F, Jaeger PF, Kohl SAA, et al. nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. Nat Methods 2021;18:203–211. Available at: http://dx.doi.org/10.1038/s41592-020-01008-z.

18. Valmaggia P, Friedli P, Hörmann B, et al. Feasibility of Automated Segmentation of Pigmented Choroidal Lesions in OCT Data With Deep Learning. Transl Vis Sci Technol 2022;11:25. Available at: http://dx.doi.org/10.1167/tvst.11.9.25.

19. Zhang Q, Sampani K, Xu M, et al. AOSLO-net: A Deep Learning-Based Method for Automatic Segmentation of Retinal Microaneurysms From Adaptive Optics Scanning Laser Ophthalmoscopy Images. Transl Vis Sci Technol 2022;11:7. Available at: http://dx.doi.org/10.1167/tvst.11.8.7.

20. Zhang G, Fu DJ, Liefers B, et al. Clinically relevant deep learning for detection and quantification of geographic atrophy from optical coherence tomography: a model development and external validation study. Lancet Digit Health 2021;3:e665–e675. Available at: http://dx.doi.org/10.1016/S2589-7500(21)00134-5.

21. Beucher S, Meyer F. The morphological approach to segmentation: The watershed transformation. In: *Mathematical Morphology in Image Processing*. CRC Press; 2018:433–481. Available at: https://www.taylorfrancis.com/chapters/edit/10.1201/9781482277234-12/morphological-approach-segmentation-watershed-transformation-beucher-meyer.

22. Zhou Y, Wagner SK, Chia MA, et al. AutoMorph: Automated Retinal Vascular Morphology Quantification Via a Deep Learning Pipeline. Transl Vis Sci Technol 2022;11:12. Available at: http://dx.doi.org/10.1167/tvst.11.7.12.

23. Cornelis SS, Runhart EH, Bauwens M, et al. Personalized genetic counseling for Stargardt disease: Offspring risk estimates based on variant severity. Am J Hum Genet 2022;109:498–507. Available at: http://dx.doi.org/10.1016/j.ajhg.2022.01.008.

24. Cornelis SS, Bauwens M, Haer-Wigman L, et al. Compendium of clinical variant classification for 2,247 unique ABCA4 variants to improve genetic medicine access for Stargardt Disease. bioRxiv 2023. Available at: https://www.medrxiv.org/content/10.1101/2023.04.24.23288782v1.

25. Fakin A, Robson AG, Fujinami K, et al. Phenotype and Progression of Retinal Degeneration Associated With Nullizigosity of ABCA4. Invest Ophthalmol Vis Sci 2016;57:4668–4678. Available at: http://dx.doi.org/10.1167/iovs.16-19829.

26. Georgiou M, Kane T, Tanna P, et al. Prospective Cohort Study of Childhood-Onset Stargardt Disease: Fundus Autofluorescence Imaging, Progression, Comparison with Adult-Onset Disease, and Disease Symmetry. Am J Ophthalmol 2020;211:159–175. Available at: http://dx.doi.org/10.1016/j.ajo.2019.11.008.

27. Fujinami K, Zernant J, Chana RK, et al. Clinical and molecular characteristics of childhood-onset Stargardt disease. Ophthalmology 2015;122:326–334. Available at: http://dx.doi.org/10.1016/j.ophtha.2014.08.012.

28. Fujinami K, Lois N, Mukherjee R, et al. A longitudinal study of Stargardt disease: quantitative assessment of fundus autofluorescence, progression, and genotype correlations. Invest Ophthalmol Vis Sci 2013;54:8181–

8190. Available at: http://dx.doi.org/10.1167/iovs.13-12104.

29. Khan KN, Kasilian M, Mahroo OAR, et al. Early Patterns of Macular Degeneration in ABCA4-Associated Retinopathy. Ophthalmology 2018;125:735–746. Available at: http://dx.doi.org/10.1016/j.ophtha.2017.11.020.

30. Zinkernagel MS, MacLaren RE. Recent advances and future prospects in choroideremia. Clin Ophthalmol 2015;9:2195–2200. Available at: http://dx.doi.org/10.2147/OPTH.S65732.

31. Syed R, Sundquist SM, Ratnam K, et al. High-resolution images of retinal structure in patients with choroideremia. Invest Ophthalmol Vis Sci 2013;54:950–961. Available at: http://dx.doi.org/10.1167/iovs.12-10707.

32. Fujinami K, Sergouniotis PI, Davidson AE, et al. Clinical and molecular analysis of Stargardt disease with preserved foveal structure and function. Am J Ophthalmol 2013;156:487-501.e1. Available at: http://dx.doi.org/10.1016/j.ajo.2013.05.003.

33. Shiraki K, Kohno T, Moriwaki M, Yanagihara N. Fundus autofluorescence in patients with pseudoxanthoma elasticum. Int Ophthalmol 2001;24:243–248. Available at: https://pubmed.ncbi.nlm.nih.gov/14531624/ [Accessed March 24, 2024].

34. Sparrow JR, Duncker T, Woods R, Delori FC. Quantitative Fundus Autofluorescence in Best Vitelliform Macular Dystrophy: RPE Lipofuscin is not Increased in Non-Lesion Areas of Retina. In: *Retinal Degenerative Diseases*. Springer International Publishing; 2016:285–290. Available at: http://dx.doi.org/10.1007/978-3-319-17121-0_38.

35. Shah M, Broadgate S, Shanks M, et al. Association of Clinical and Genetic Heterogeneity With BEST1 Sequence Variations. JAMA Ophthalmol 2020. Available at: http://dx.doi.org/10.1001/jamaophthalmol.2020.0666.

36. Laich Y, Georgiou M, Fujinami K, et al. Best Vitelliform Macular Dystrophy Natural History Study Report 1: Clinical Features and Genetic Findings. Ophthalmology 2024. Available at: http://dx.doi.org/10.1016/j.ophtha.2024.01.027.

37. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet 2006;368:1795–1809. Available at: https://pubmed.ncbi.nlm.nih.gov/17113430/ [Accessed March 24, 2024].

38. Cideciyan AV, Jacobson SG. Leber congenital amaurosis (LCA): Potential for improvement of vision. Invest Ophthalmol Vis Sci 2019;60:1680. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892385/ [Accessed March 24, 2024].

39. Huang D, Heath Jeffery RC, Aung-Htut MT, et al. Stargardt disease and progress in therapeutic strategies. Ophthalmic Genet 2022;43:1–26. Available at: http://dx.doi.org/10.1080/13816810.2021.1966053.

40. Lee W, Zernant J, Nagasaki T, et al. Cis-acting modifiers in the ABCA4 locus contribute to the penetrance of the major disease-causing variant in Stargardt disease. Hum Mol Genet 2021;30:1293–1304. Available at: http://dx.doi.org/10.1093/hmg/ddab122.

41. Fujinami K, Sergouniotis PI, Davidson AE, et al. The clinical effect of homozygous ABCA4 alleles in 18 patients. Ophthalmology 2013;120:2324–2331. Available at: http://dx.doi.org/10.1016/j.ophtha.2013.04.016.

42. Fakin A, Robson AG, Chiang JP-W, et al. The Effect on Retinal Structure and Function of 15 Specific ABCA4 Mutations: A Detailed Examination of 82 Hemizygous Patients. Invest Ophthalmol Vis Sci 2016;57:5963–5973. Available at: http://dx.doi.org/10.1167/iovs.16-20446.

43. Grob S, Yonekawa Y, Eliott D. Multimodal imaging of adult-onset foveomacular vitelliform dystrophy. Saudi J Ophthalmol 2014;28:104–110. Available at: http://dx.doi.org/10.1016/j.sjopt.2014.02.001.

44. Strauss RW, Ho A, Jha A, et al. Progression of Stargardt Disease as Determined by Fundus Autofluorescence Over a 24-Month Period (ProgStar Report No. 17). Am J Ophthalmol 2023;250:157–170. Available at: http://dx.doi.org/10.1016/j.ajo.2023.02.003.

45. Antonelli G, Parravano M, Barbano L, et al. Multimodal Study of PRPH2 Gene-Related Retinal Phenotypes. Diagnostics (Basel) 2022;12. Available at: http://dx.doi.org/10.3390/diagnostics12081851.

46. Daich Varela M, Georgiadis A, Michaelides M. Genetic treatment for autosomal dominant inherited retinal dystrophies: approaches, challenges and targeted genotypes. Br J Ophthalmol 2023;107:1223–1230. Available at: http://dx.doi.org/10.1136/bjo-2022-321903.

47. Miere A, Le Meur T, Bitton K, et al. Deep Learning-Based Classification of Inherited Retinal Diseases Using Fundus Autofluorescence. J Clin Med Res 2020;9. Available at: http://dx.doi.org/10.3390/jcm9103303.

48. Miere A, Capuano V, Kessler A, et al. Deep learning-based classification of retinal atrophy using fundus autofluorescence imaging. Comput Biol Med 2021;130:104198. Available at: http://dx.doi.org/10.1016/j.compbiomed.2020.104198.

49. Pontikos N, Woof W, Veturi A, et al. Eye2Gene: prediction of causal inherited retinal disease gene from multimodal imaging using deep-learning. Research Square 2022. Available at: https://www.researchsquare.com/article/rs-2110140/latest [Accessed March 11, 2024].

50. Fujinami-Yokokawa Y, Ninomiya H, Liu X, et al. Prediction of causative genes in inherited retinal disorder from fundus photography and autofluorescence imaging using deep learning techniques. British Journal of Ophthalmology 2021;105:1272–1279. Available at: http://dx.doi.org/10.1136/bjophthalmol-2020-318544.

51. Lambertus S, Lindner M, Bax NM, et al. Progression of Late-Onset Stargardt Disease. Invest Ophthalmol Vis Sci 2016;57:5186–5191. Available at: http://dx.doi.org/10.1167/iovs.16-19833.

52. Ervin A-M, Strauss RW, Ahmed MI, et al. A Workshop on Measuring the Progression of Atrophy Secondary to Stargardt Disease in the ProgStar Studies: Findings and Lessons Learned. Transl Vis Sci Technol 2019;8:16. Available at: http://dx.doi.org/10.1167/tvst.8.2.16.

53. Strauss RW, Muñoz B, Ho A, et al. Progression of Stargardt Disease as Determined by Fundus Autofluorescence in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 9). JAMA Ophthalmol 2017;135:1232–1241. Available at: http://dx.doi.org/10.1001/jamaophthalmol.2017.4152.

54. Heath Jeffery RC, Thompson JA, Lo J, et al. Atrophy Expansion Rates in Stargardt Disease Using Ultra-Widefield Fundus Autofluorescence. Ophthalmol Sci 2021;1:100005. Available at: http://dx.doi.org/10.1016/j.xops.2021.100005.

55. Zhao PY, Branham K, Schlegel D, et al. Automated Segmentation of Autofluorescence Lesions in Stargardt Disease. Ophthalmol Retina 2022;6:1098–1104. Available at: http://dx.doi.org/10.1016/j.oret.2022.05.020.

56. Hull S, Arno G, Plagnol V, et al. The phenotypic variability of retinal dystrophies associated with mutations in CRX, with report of a novel macular dystrophy phenotype. Invest Ophthalmol Vis Sci 2014;55:6934–6944. Available at: http://dx.doi.org/10.1167/iovs.14-14715.

57. Fujinami-Yokokawa Y, Fujinami K, Kuniyoshi K, et al. Clinical and Genetic Characteristics of 18 Patients from 13 Japanese Families with CRX-associated retinal disorder: Identification of Genotype-phenotype Association. Sci Rep 2020;10:9531. Available at: http://dx.doi.org/10.1038/s41598-020-65737-z.

58. Fujinami-Yokokawa Y, Yang L, Joo K, et al. Occult Macular Dysfunction Syndrome: Identification of Multiple Pathologies in a Clinical Spectrum of Macular Dysfunction with Normal Fundus in East Asian Patients: EAOMD Report No. 5. Genes 2023;14. Available at: http://dx.doi.org/10.3390/genes14101869.

59. Awadh Hashem S, Georgiou M, Ali RR, Michaelides M. RPGR-Related Retinopathy: Clinical Features, Molecular Genetics, and Gene Replacement Therapy. Cold Spring Harb Perspect Med 2023. Available at: http://dx.doi.org/10.1101/cshperspect.a041280.

60. Tee JJL, Kalitzeos A, Webster AR, et al. QUANTITATIVE ANALYSIS OF HYPERAUTOFLUORESCENT RINGS TO CHARACTERIZE THE NATURAL HISTORY AND PROGRESSION IN RPGR-ASSOCIATED RETINOPATHY. Retina 2018;38:2401–2414. Available at: http://dx.doi.org/10.1097/IAE.00000000001871.

61. Cideciyan AV, Swider M, Aleman TS, et al. Reduced-illuminance autofluorescence imaging in ABCA4associated retinal degenerations. J Opt Soc Am A Opt Image Sci Vis 2007;24:1457–1467. Available at: http://dx.doi.org/10.1364/josaa.24.001457.

62. Shi C, Lee J, Wang G, et al. Assessment of image quality on color fundus retinal images using the automatic retinal image analysis. Sci Rep 2022;12:10455. Available at: http://dx.doi.org/10.1038/s41598-022-13919-2.

63. Hart WE, Goldbaum M, Côté B, et al. Measurement and classification of retinal vascular tortuosity. Int J Med Inform 1999;53:239–252. Available at: http://dx.doi.org/10.1016/s1386-5056(98)00163-4.

64. Grisan E, Foracchia M, Ruggeri A. A novel method for the automatic grading of retinal vessel tortuosity. IEEE Trans Med Imaging 2008;27:310–319. Available at: http://dx.doi.org/10.1109/TMI.2007.904657.